

**Interaction Report**

**Report ID:**  
**Date Produced:** 18 October 2021

**Antiretroviral Treatment****Co-medications**

Efavirenz (EFV)  
Emtricitabine (FTC)  
Tenofovir-DF (TDF)

Furosemide

This report lists the summaries of potential interactions (i.e. "red", "amber" and "yellow" classifications) for the drugs in the table above.

Interactions with a "green" or "grey" classification (i.e. no clinically significant interaction or no clear data) have been checked and are listed at the end of this report, but summaries are not shown.

For full details of all interactions, see [www.hiv-druginteractions.org](http://www.hiv-druginteractions.org).

**Description of the interactions**

Potential weak interaction - additional action/monitoring or dosage adjustment is unlikely to be required (YELLOW)

**Tenofovir-DF (TDF) + Furosemide**

Coadministration has not been studied. Furosemide is glucuronidated mainly in the kidney (UGT1A9) and to a lesser extent in the liver (UGT1A1). A large proportion of furosemide is also eliminated unchanged renally (via OATs). In vitro data indicate that furosemide is a weak inhibitor of the renal transporters OAT1/OAT3 and therefore is predicted to have a limited effect on tenofovir renal elimination. No a priori dosage adjustment is recommended.

No clinically significant interaction expected (GREEN)

Efavirenz (EFV) + Furosemide

Emtricitabine (FTC) + Furosemide